Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000760617 | SCV000890509 | pathogenic | not provided | 2018-07-06 | criteria provided, single submitter | clinical testing | The Q164X variant in the GMPPB gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The Q164X variant is not observed in large population cohorts (Lek et al., 2016). We interpret Q164X as a pathogenic variant. |
Labcorp Genetics |
RCV005213382 | SCV005861300 | pathogenic | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14; Autosomal recessive limb-girdle muscular dystrophy type 2T | 2024-09-04 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln164*) in the GMPPB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GMPPB are known to be pathogenic (PMID: 23768512, 26310427). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with GMPPB-related conditions. ClinVar contains an entry for this variant (Variation ID: 620253). For these reasons, this variant has been classified as Pathogenic. |